{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:33:34Z","timestamp":1773203614208,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T00:00:00Z","timestamp":1507248000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan","award":["20590718"],"award-info":[{"award-number":["20590718"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00228-017-2324-1","type":"journal-article","created":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T14:04:17Z","timestamp":1507298657000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin"],"prefix":"10.1007","volume":"74","author":[{"given":"Takahiro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Uotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moriya","family":"Iwaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,6]]},"reference":[{"key":"2324_CR1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0889-8553(21)00664-6","volume":"19","author":"SJ Sontag","year":"1990","unstructured":"Sontag SJ (1990) The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin N Am 19:683\u2013712","journal-title":"Gastroenterol Clin N Am"},{"issue":"Suppl 1","key":"2324_CR2","first-page":"27","volume":"39","author":"EC Klinkenberg-Knol","year":"1992","unstructured":"Klinkenberg-Knol EC (1992) The role of omeprazole in healing and prevention of reflux disease. Hepato-Gastroenterology 39(Suppl 1):27\u201330","journal-title":"Hepato-Gastroenterology"},{"key":"2324_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/j.1875-9114.1993.tb02689.x","volume":"13","author":"F Massoomi","year":"1993","unstructured":"Massoomi F, Savage J, Destache CJ (1993) Omeprazole: a comprehensive review. Pharmacotherapy 13:46\u201359","journal-title":"Pharmacotherapy"},{"issue":"Suppl B","key":"2324_CR4","first-page":"2","volume":"15","author":"G Dobrilla","year":"1993","unstructured":"Dobrilla G, Di Fede F (1993) Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. Clin Ther 15(Suppl B):2\u201313","journal-title":"Clin Ther"},{"key":"2324_CR5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1067\/mcp.2002.127637","volume":"72","author":"T Furuta","year":"2002","unstructured":"Furuta T, Shirai N, Watanabe F et al (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453\u2013460","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"2324_CR6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000200917","volume":"51","author":"NJ Bell","year":"1992","unstructured":"Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51(Suppl 1):59\u201367","journal-title":"Digestion"},{"key":"2324_CR7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1046\/j.1365-2036.1998.00419.x","volume":"12","author":"PO Katz","year":"1998","unstructured":"Katz PO, Anderson C, Khoury R, Castell DO (1998) Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 12:1231\u20131234","journal-title":"Aliment Pharmacol Ther"},{"key":"2324_CR8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1572-0241.1998.221_a.x","volume":"93","author":"PL Peghini","year":"1998","unstructured":"Peghini PL, Katz PO, Bracy NA, Castell DO (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763\u2013767","journal-title":"Am J Gastroenterol"},{"key":"2324_CR9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H et al (2016) Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 43:1048\u20131059","journal-title":"Aliment Pharmacol Ther"},{"key":"2324_CR10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H et al (2015) Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014a randomised open-label cross-over study. Aliment Pharmacol Ther 42:719\u2013730","journal-title":"Aliment Pharmacol Ther"},{"key":"2324_CR11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T et al (2016) Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43:240\u2013251","journal-title":"Aliment Pharmacol Ther"},{"key":"2324_CR12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/apt.12012","volume":"36","author":"CS Jianu","year":"2012","unstructured":"Jianu CS, Fossmark R, Viset T et al (2012) Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 36:644\u2013649","journal-title":"Aliment Pharmacol Ther"},{"key":"2324_CR13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10620-015-4014-0","volume":"61","author":"N Nandy","year":"2016","unstructured":"Nandy N, Hanson JA, Strickland RG, McCarthy DM (2016) Solitary gastric carcinoid tumor associated with long-term use of omeprazole: a case report and review of the literature. Dig Dis Sci 61:708\u2013712","journal-title":"Dig Dis Sci"},{"key":"2324_CR14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/00365521.2011.627444","volume":"47","author":"CS Jianu","year":"2012","unstructured":"Jianu CS, Lange OJ, Viset T et al (2012) Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 47:64\u201367","journal-title":"Scand J Gastroenterol"},{"key":"2324_CR15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/apm.12380","volume":"123","author":"R Fossmark","year":"2015","unstructured":"Fossmark R, Sagatun L, Nordrum IS, Sandvik AK, Waldum HL (2015) Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival. APMIS : Acta Pathol Microbiol Immunol Scand 123:509\u2013514","journal-title":"APMIS : Acta Pathol Microbiol Immunol Scand"},{"key":"2324_CR16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clpt.2004.10.010","volume":"77","author":"M Sugimoto","year":"2005","unstructured":"Sugimoto M, Furuta T, Shirai N et al (2005) Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 77:302\u2013311","journal-title":"Clin Pharmacol Ther"},{"key":"2324_CR17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1046\/j.1365-2036.2000.00799.x","volume":"14","author":"T Katsube","year":"2000","unstructured":"Katsube T, Adachi K, Kawamura A et al (2000) Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049\u20131056","journal-title":"Aliment Pharmacol Ther"},{"key":"2324_CR18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1046\/j.1365-2036.2001.01050.x","volume":"15","author":"S Xue","year":"2001","unstructured":"Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO (2001) Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 15:1351\u20131356","journal-title":"Aliment Pharmacol Ther"},{"key":"2324_CR19","first-page":"G752","volume":"265","author":"A Tari","year":"1993","unstructured":"Tari A, Yamamoto G, Sumii K et al (1993) Role of histamine 2 receptor in increased expression of rat gastric H(+)-K(+)-ATPase alpha-subunit induced by omeprazole. Am J Phys 265:G752\u2013G758","journal-title":"Am J Phys"},{"key":"2324_CR20","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1007\/BF02208679","volume":"40","author":"G Yamamoto","year":"1995","unstructured":"Yamamoto G, Tari A, Sumii K, Sumii M, Haruma K, Kajiyama G (1995) Famotidine, a histamine-2-receptor antagonist, inhibits the increase in rat gastric H+\/K(+)-ATPase mRNA induced by intravenous infusion of gastrin 17 and histamine. Dig Dis Sci 40:2064\u20132069","journal-title":"Dig Dis Sci"},{"key":"2324_CR21","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1440-1746.2006.04721.x","volume":"22","author":"T Ichikawa","year":"2007","unstructured":"Ichikawa T, Ota H, Sugiyama A et al (2007) Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa. J Gastroenterol Hepatol 22:1800\u20131805","journal-title":"J Gastroenterol Hepatol"},{"key":"2324_CR22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejphar.2011.02.007","volume":"658","author":"M Nakano","year":"2011","unstructured":"Nakano M, Kitano S, Nanri M, Kiniwa M (2011) Lafutidine, a unique histamine H2-receptor antagonist, inhibits distention-induced gastric acid secretion through an H2 receptor-independent mechanism. Eur J Pharmacol 658:236\u2013241","journal-title":"Eur J Pharmacol"},{"key":"2324_CR23","first-page":"79","volume":"68","author":"T Sano","year":"2017","unstructured":"Sano T, Utsumi D, Amagase K et al (2017) Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons. J Physiol Pharmacol: Off J Polish Physiol Soc 68:79\u201390","journal-title":"J Physiol Pharmacol: Off J Polish Physiol Soc"},{"key":"2324_CR24","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s10620-014-3489-4","volume":"60","author":"EH Kim","year":"2015","unstructured":"Kim EH, Lee YC, Chang YW et al (2015) Efficacy of lafutidine versus famotidine in patients with reflux esophagitis: a multi-center, randomized, double-blind, non-inferiority phase III trial. Dig Dis Sci 60:1724\u20131732","journal-title":"Dig Dis Sci"},{"key":"2324_CR25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1248\/bpb.25.379","volume":"25","author":"H Itoh","year":"2002","unstructured":"Itoh H, Naito T, Takeyama M (2002) Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma. Biol Pharm Bull 25:379\u2013382","journal-title":"Biol Pharm Bull"},{"key":"2324_CR26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3748\/wjg.v23.i4.668","volume":"23","author":"K Sakurai","year":"2017","unstructured":"Sakurai K, Suda H, Ido Y et al (2017) Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 23:668\u2013675","journal-title":"World J Gastroenterol"},{"key":"2324_CR27","first-page":"1163","volume":"73","author":"K Sugano","year":"2015","unstructured":"Sugano K (2015) Vonoprazan: a novel potassium-competitive acid blocker. Nihon rinsho Jpn J Clin Med 73:1163\u20131168","journal-title":"Nihon rinsho Jpn J Clin Med"},{"key":"2324_CR28","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1136\/gut.29.10.1364","volume":"29","author":"S Lanzon-Miller","year":"1988","unstructured":"Lanzon-Miller S, Pounder RE, Chronos NA, Raymond F, Hamilton MR, Dalgleish D (1988) Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h. Gut 29:1364\u20131369","journal-title":"Gut"},{"key":"2324_CR29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/gut.24.1.61","volume":"24","author":"R Mohammed","year":"1983","unstructured":"Mohammed R, Holden RJ, Hearns JB, McKibben BM, Buchanan KD, Crean GP (1983) Effects of eight weeks\u2019 continuous treatment with oral ranitidine and cimetidine on gastric acid secretion, pepsin secretion, and fasting serum gastrin. Gut 24:61\u201366","journal-title":"Gut"},{"key":"2324_CR30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/00365528809103975","volume":"23","author":"S Lanzon-Miller","year":"1988","unstructured":"Lanzon-Miller S, Pounder RE, Ball SG, Dalgleish DJ, Coward J, Jackson AO (1988) The effects of famotidine, 40 mg at night, on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Scand J Gastroenterol 23:244\u2013250","journal-title":"Scand J Gastroenterol"},{"key":"2324_CR31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2710.2006.00749.x","volume":"31","author":"K Ikawa","year":"2006","unstructured":"Ikawa K, Shimatani T, Azuma Y, Inoue M, Morikawa N (2006) Calcitonin gene-related peptide and somatostatin releases correlated with the area under the lafutidine concentration-time curve in human plasma. J Clin Pharm Ther 31:351\u2013356","journal-title":"J Clin Pharm Ther"},{"key":"2324_CR32","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"DE Freedberg","year":"2017","unstructured":"Freedberg DE, Kim LS, Yang YX (2017) The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 152:706\u2013715","journal-title":"Gastroenterology"},{"key":"2324_CR33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/019262338801600220","volume":"16","author":"H Larsson","year":"1988","unstructured":"Larsson H, Hakanson R, Mattsson H, Ryberg B, Sundler F, Carlsson E (1988) Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 16:267\u2013272","journal-title":"Toxicol Pathol"},{"key":"2324_CR34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000200245","volume":"45","author":"N Havu","year":"1990","unstructured":"Havu N, Mattsson H, Ekman L, Carlsson E (1990) Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45:189\u2013195","journal-title":"Digestion"},{"key":"2324_CR35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0016-5085(86)90938-8","volume":"90","author":"H Larsson","year":"1986","unstructured":"Larsson H, Carlsson E, Mattsson H et al (1986) Plasma gastrin and gastric enterochromaffin\u00adlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90:391\u2013399","journal-title":"Gastroenterology"},{"key":"2324_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/00365528609090884","volume":"118","author":"E Carlsson","year":"1986","unstructured":"Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G (1986) Pharmacology and toxicology of omeprazole\u2014with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl 118:31\u201338","journal-title":"Scand J Gastroenterol Suppl"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2324-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2324-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2324-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T15:28:55Z","timestamp":1719502135000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2324-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,6]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["2324"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2324-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,6]]}}}